Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity

Vaccine

Volumn 29, Issue 1, 2010, Pages 130-140

  Wanjalla, Celestine N ^a   Faul, Elizabeth J ^a   Gomme, Emily A ^a   Schnell, Matthias J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

DC vaccines; Dendritic cells; HIV; Rabies virus; Rhabdoviruses

Indexed keywords

CYTOKINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RABIES VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; HUMORAL IMMUNITY; IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; VACCINIA VIRUS;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV ANTIBODIES; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; RABIES VACCINES; RABIES VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 78649710022     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.042     Document Type: Article

References (55)

1. UNAIDS. 2008 Report on the global AIDS epidemic; 2008.
2. Monath T.P. Yellow fever vaccine. Expert Rev Vaccines 2005, 4(4 (August)):553-574.
3. Ogra P.L. Poliomyelitis as a paradigm for investment in and success of vaccination programs. Pediatr Infect Dis J 1999 Jan, 18(1):10-15.
4. Barron M.A., Blyveis N., Palmer B.E., MaWhinney S., Wilson C.C. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis 2003, 187(1 (January)):26-37.
5. Pacanowski J., Kahi S., Baillet M., Lebon P., Deveau C., Goujard C., et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001, 98(10 (November)):3016-3021.
6. Connolly N.C., Colleton B.A., Rinaldo C.R. Treating HIV-1 infection with dendritic cells. Curr Opin Mol Ther 2007, 9(4 (August)):353-363.
7. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673 (March)):245-252.
8. Steinman R. Dendritic cells: understanding immunogenicity. Eur J Immunol 2007, 37(S1 (October)):S53-S60.
9. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109(12 (June)):1519-1526.
10. Andrieu J.M., Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J Intern Med 2007, 261(2 (February)):123-131.
11. Engelmayer J., Larsson M., Lee A., Lee M., Cox W.I., Steinman R.M., et al. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol 2001, 75(5 (March)):2142-2153.
12. Furukawa S., Akbar S.M., Hasebe A., Horiike N., Onji M. Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: evaluation of immunogenicity of antigen-pulsed dendritic cells in vivo. Immunobiology 2004, 209(7):551-557.
13. Xiang M., Eisenbach C., Lupu C.M., Ernst E., Stremmel W., Encke J. Induction of antigen-specific immune responses in vivo after vaccination with dendritic cells transduced with adenoviral vectors encoding hepatitis C virus NS3. Viral Immunol 2006, 19(2 (Summer)):210-219.
14. Lu W., Wu X., Lu Y., Guo W., Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003, 9(1 (January)):27-32.
15. Lapenta C., Santini S.M., Logozzi M., Spada M., Andreotti M., Di Pucchio T., et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 2003, 198(2 (July)):361-367.
16. Coslett G.D., Holloway B.P., Obijeski J.F. The structural proteins of rabies virus and evidence for their synthesis from separate monocistronic RNA species. J Gen Virol 1980, 49(1 (July)):161-180.
17. Schnell M.J., Mebatsion T., Conzelmann K.K. Infectious rabies viruses from cloned cDNA. EMBO J 1994, 13(18 (September)):4195-4203.
18. Mebatsion T., Schnell M.J., Cox J.H., Finke S., Conzelmann K.K. Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci USA 1996, 93(14 (July)):7310-7314.
19. Siler C.A., McGettigan J.P., Dietzschold B., Herrine S.K., Dubuisson J., Pomerantz R.J., et al. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 2002, 292(1 (January)):24-34.
20. Smith M.E., Koser M., Xiao S., Siler C., McGettigan J.P., Calkins C., et al. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 2006, 353(2 (September)):344-356.
21. McKenna P.M., McGettigan J.P., Pomerantz R.J., Dietzschold B., Schnell M.J. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res 2003, 1(2 (April)):229-237.
22. Schnell M.J., Foley H.D., Siler C.A., McGettigan J.P., Dietzschold B., Pomerantz R.J. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci USA 2000, 97(7 (March)):3544-3549.
23. Tan G.S., McKenna P.M., Koser M.L., McLinden R., Kim J.H., McGettigan J.P., et al. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 2005, 331(1 (January)):82-93.
24. Gomme E.A., Faul E.J., Flomenberg P., McGettigan J.P., Schnell M.J. Characterization of a single-cycle rabies virus-based vaccine vector. J Virol 2010, 84(6 (March)):2820-2831.
25. Mebatsion T. Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein. J Virol 2001, 75(23 (December)):11496-11502.
26. Faul E.J., Wanjalla C.N., McGettigan J.P., Schnell M.J. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 2008, 382(2 (December)):226-238.
27. Li J., McGettigan J.P., Faber M., Schnell M.J., Dietzschold B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFkappaB signaling pathway. Vaccine 2008, 26(3 (January)):419-426.
28. Connolly N.C., Whiteside T.L., Wilson C., Kondragunta V., Rinaldo C.R., Riddler S.A. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008, 15(2 (February)):284-292.
29. Whiteside T.L., Piazza P., Reiter A., Stanson J., Connolly N.C., Rinaldo C.R., et al. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2009, 16(2 (February)):233-240.
30. Koser M.L., McGettigan J.P., Tan G.S., Smith M.E., Koprowski H., Dietzschold B., et al. Rabies virus nucleoprotein as a carrier for foreign antigens. Proc Natl Acad Sci USA 2004, 101(25 (June)):9405-9410.
31. McGettigan J.P., Foley H.D., Belyakov I.M., Berzofsky J.A., Pomerantz R.J., Schnell M.J. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol 2001, 75(9 (May)):4430-4434.
32. McGettigan J.P., Pomerantz R.J., Siler C.A., McKenna P.M., Foley H.D., Dietzschold B., et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 2003, 77(1 (January)):237-244.
33. Snook A.E., Li P., Stafford B.J., Faul E.J., Huang L., Birbe R.C., et al. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res 2009, 69(8 (April)):3537-3544.
34. Inaba K., Swiggard W.J., Steinman R.M., Romani N., Schuler G. Isolation of dendritic cells. Curr Protoc Immunol 2001, (May). Unit 3, 7 [Chapter 3].
35. Lecoeur H., Ledru E., Prevost M.C., Gougeon M.L. Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods. J Immunol Methods 1997, 209(2 (December)):111-123.
36. Foley H.D., Otero M., Orenstein J.M., Pomerantz R.J., Schnell M.J. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol 2002, 76(1 (January)):19-31.
37. Restifo N.P. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol 2000, 12(5 (October)):597-603.
38. Nicollete C.A. Dendritic cells for active immunotherapy: Optimizing design and man in order to develop commercially and clinically viable products. Vaccine 2007, 25(Suppl. 2 (September)):B47-B60.
39. Ahmed M., Brzoza K.L., Hiltbold E.M. Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J Virol 2006, 80(5 (March)):2194-2205.
40. Faul E.J., Wanjalla C.N., Suthar M.S., Gale M., Wirblich C., Schnell M.J. Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling. PLoS Pathog 2010, 6(7):e1001016.
41. Prehaud C., Lay S., Dietzschold B., Lafon M. Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis. J Virol 2003, 77(19 (October)):10537-10547.
42. Faul E.J., Aye P.P., Papaneri A.B., Pahar B., McGettigan J.P., Schiro F., et al. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 2009, 28(2 (December)):299-308.
43. McGettigan J.P., Koser M.L., McKenna P.M., Smith M.E., Marvin J.M., Eisenlohr L.C., et al. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology 2006, 344(2 (January)):363-377.
44. McGettigan J.P., Naper K., Orenstein J., Koser M., McKenna P.M., Schnell M.J. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol 2003, 77(20 (October)):10889-10899.
45. McGettigan J.P., Sarma S., Orenstein J.M., Pomerantz R.J., Schnell M.J. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol 2001, 75(18 (September)):8724-8732.
46. McKenna P.M., Koser M.L., Carlson K.R., Montefiori D.C., Letvin N.L., Papaneri A.B., et al. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis 2007, 195(7 (April)):980-988.
47. Gruber A., Chalmers A.S., Rasmussen R.A., Ong H., Popov S., Andersen J., et al. Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol 2007, 20(1 (Spring)):160-169.
48. Cenna J., Hunter M., Tan G.S., Papaneri A.B., Ribka E.P., Schnell M.J., et al. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis 2009, 200(8 (October)):1251-1260.
49. Engelmayer J., Larsson M., Subklewe M., Chahroudi A., Cox W.I., Steinman R.M., et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 1999, 163(12 (December)):6762-6768.
50. Grosjean I., Caux C., Bella C., Berger I., Wild F., Banchereau J., et al. Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. J Exp Med 1997, 186(6 (September)):801-812.
51. Salio M., Cella M., Suter M., Lanzavecchia A. Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol 1999, 29(10 (October)):3245-3253.
52. Vidy A., Chelbi-Alix M., Blondel D. Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J Virol 2005, 79(22 (November)):14411-14420.
53. Kleindienst P., Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol 2003, 170(6 (March)):2817-2823.
54. Gandhi R.T., O'Neill D., Bosch R.J., Chan E.S., Bucy R.P., Shopis J., et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27(43 (October)):6088-6094.
55. Dai B., Yang L., Yang H., Hu B., Baltimore D., Wang P. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA 2009, 106(48 (December)):20382-20387.